Titan Pharmaceuticals(TTNP) - 2022 Q2 - Quarterly Report
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the transition period from ____ to ____ Commission File Number 001-13341 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Delaware | 94-3171940 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | 400 Oyster Point Blvd., Suite 505, South San Francisco, California 94080 (Address of principal execu ...